Table 2.

Summary of patients' characteristics (n = 114) and baseline serum marker values

Patient characteristicsn (%)a
Age, y; median (range)At diagnosis61 (36–79)
At registration64 (39–80)
RaceWhite103 (90.4)
Not white11 (9.6)
Histology at diagnosisAdenocarcinoma
GS 5/65 (4.4)
GS 715 (13.2)
GS 813 (11.4)
GS 953 (46.5)
GS 107 (6.0)
Small-cell carcinoma8 (7.0)
Not available13 (11.4)
Radiation to primary tumorYes16 (14)
No98 (86)
Surgery to primary tumorYes30 (73.7)
No84 (26.3)
ECOG PS at registration025 (21.9)
174 (64.9)
215 (13.2)
Serum markersIULNNo. (%) with values > IULNMedian (range)
ACTHpmol/L10.14/111 (3.6)4.3 (0.88–47.3)
ADHpmol/L12.37/74 (9.5)2.9 (0.9–270.4)
AVPpg/mL1.75/36 (13.9)0.9 (<0.5–3.6)
Alkaline phosIU/L12644/104 (42.3)103.5 (40–1,107)
Calcitoninpmol/L2.528/88 (31.8)1.5 (0.3–1,079.8)
Bone-sp Alkaline phosμg/L2048/108 (44.4)16.95 (1.8–404)
CEAμg/L3–628/113 (24.8)2.5 (0–979.4)
Chromogranin Aμg/L36.417/74 (23.0)16.6 (4–615.7)
Chromogranin A,Sμg/L22520/35 (57.1)251 (4–9,850)
GRPpg/mL5000/57 (0)58 (39–442)
Hemoglobing/L14078/114 (68.4)127 (81–159)
LDHIU/L54652/114 (45.6)527 (111–1,942)
PAPng/mL555/111 (49.5)4.5 (0.5–2,464.8)
PSAμg/L472/114 (63.2)8.7 (0–924.7)
Somatostatinpmol/L13.422/106 (20.8)10.7 (3.1–33.6)

Abbreviations: GS, Gleason score; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ACTH, adrenocorticotropic hormone; ADH, antidiuretic hormone; AVP, arginine vasopressin; Alkaline phos, alkaline phosphatase; Bone-sp, bone specific; GRP, gastrin-releasing peptide.

  • aData are given as numbers (and percentages) unless otherwise indicated.